Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748872 · ClinicalTrials.gov registry record · Phase 1
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
A Phase 1 study, sponsored by Medigene.
- Not yet
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT06748872 is a Phase 1 study that has not yet begun recruiting, run by Medigene. The registered enrollment target is 55 participants.
The verdict
NCT06748872, a Phase 1 study, has not yet begun recruiting, sponsored by Medigene.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The study purpose is to establish the safety, tolerability and preliminary efficacy of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma that expresses NY-ESO-1 and/or LAGE-1a. The main questions this clinical trial aims to answer are: Can this TCR-T therapy MDG1015 be given to patients safely? What is the optimal dose of the TCR-T therapy MDG1015? If and what side effects do participants experience after receiving the TCR-T therapy MDG1015? Do participants experience a potential disease response after receiving the TCR-T therapy MDG1015? Participants will: Receive (in most cases) 1 single infusion of MDG1015 at a pre-defined dose level and will be followed up regularly up to 1 year. After one year, participants will enter the long term follow-up part up to 15 years after being treated. Any side effects and/or potential disease response will be documented during this period.
Interventions
- DRUG Lymphodepletion
- BIOLOGICAL TCR-T cells (MDG1015)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2042-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06748872
The ClinicalTrials.gov registry entry for NCT06748872 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medigene, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lymphodepletion is the first listed.
NCT06748872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06748872 about?
NCT06748872 is a clinical study titled "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma". MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The study purpose is to establish the safety, tolerability and preliminary efficacy of MDG1015 in patients with epithelial ovarian cancer, gastroeso...
What is the current status of trial NCT06748872?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2025-07-01. Estimated completion is 2042-08-01.
What interventions are being tested in trial NCT06748872?
The interventions under investigation include: Lymphodepletion (DRUG), TCR-T cells (MDG1015) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06748872?
This trial is sponsored by Medigene, which has 1 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.